Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy

Mary Eapen, Brent R. Logan, Fredrick R. Appelbaum, Joseph H. Antin, Claudio Anasetti, Daniel R. Couriel, Junfang Chen, Richard Maziarz, Philip L. McCarthy, Ryotaro Nakamura, Voravit Ratanatharathorn, Ravi Vij, Richard E. Champlin

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We sought to determine whether differences in chronic graft-versus-host disease (GVHD) rates would lead to survival differences by comparing 2463 peripheral blood (PB) and 1713 bone marrow (BM) hematopoietic cell transplant recipients. Patients had acute leukemia, chronic myeloid leukemia (CML), or myelodysplastic syndrome, and they received myeloablative conditioning regimens and calcineurin-inhibitor GVHD prophylaxis. There were no significant differences in long-term survival after transplantation of PB and BM, except for patients in first chronic phase CML. For these patients, the 5-year rate of survival was lower after transplantation of PB compared with transplantation of BM (35% versus 56%, P= .001). Although mortality risks were higher in patients with chronic GVHD after both PB (hazard ratio [HR], 1.58; P <.001) and BM (HR 1.73; P <.001) transplantations, its effect on mortality did not differ by graft type (P= .42). BM is the preferred graft for first chronic phase CML, whereas as either graft is suitable for other leukemias.

Original languageEnglish (US)
Pages (from-to)55-59
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Unrelated Donors
Hematologic Neoplasms
Bone Marrow Cells
Graft vs Host Disease
Transplantation
Leukemia, Myeloid, Chronic Phase
Transplants
Survival
Bone Marrow
Leukemia
Mortality
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Survival Rate

Keywords

  • Chronic graft-versus-host disease
  • Leukemia
  • Mortality

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. / Eapen, Mary; Logan, Brent R.; Appelbaum, Fredrick R.; Antin, Joseph H.; Anasetti, Claudio; Couriel, Daniel R.; Chen, Junfang; Maziarz, Richard; McCarthy, Philip L.; Nakamura, Ryotaro; Ratanatharathorn, Voravit; Vij, Ravi; Champlin, Richard E.

In: Biology of Blood and Marrow Transplantation, Vol. 21, No. 1, 01.01.2015, p. 55-59.

Research output: Contribution to journalArticle

Eapen, M, Logan, BR, Appelbaum, FR, Antin, JH, Anasetti, C, Couriel, DR, Chen, J, Maziarz, R, McCarthy, PL, Nakamura, R, Ratanatharathorn, V, Vij, R & Champlin, RE 2015, 'Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy', Biology of Blood and Marrow Transplantation, vol. 21, no. 1, pp. 55-59. https://doi.org/10.1016/j.bbmt.2014.09.006
Eapen, Mary ; Logan, Brent R. ; Appelbaum, Fredrick R. ; Antin, Joseph H. ; Anasetti, Claudio ; Couriel, Daniel R. ; Chen, Junfang ; Maziarz, Richard ; McCarthy, Philip L. ; Nakamura, Ryotaro ; Ratanatharathorn, Voravit ; Vij, Ravi ; Champlin, Richard E. / Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. In: Biology of Blood and Marrow Transplantation. 2015 ; Vol. 21, No. 1. pp. 55-59.
@article{084b172ce5f34007993048235e6b3740,
title = "Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy",
abstract = "We sought to determine whether differences in chronic graft-versus-host disease (GVHD) rates would lead to survival differences by comparing 2463 peripheral blood (PB) and 1713 bone marrow (BM) hematopoietic cell transplant recipients. Patients had acute leukemia, chronic myeloid leukemia (CML), or myelodysplastic syndrome, and they received myeloablative conditioning regimens and calcineurin-inhibitor GVHD prophylaxis. There were no significant differences in long-term survival after transplantation of PB and BM, except for patients in first chronic phase CML. For these patients, the 5-year rate of survival was lower after transplantation of PB compared with transplantation of BM (35{\%} versus 56{\%}, P= .001). Although mortality risks were higher in patients with chronic GVHD after both PB (hazard ratio [HR], 1.58; P <.001) and BM (HR 1.73; P <.001) transplantations, its effect on mortality did not differ by graft type (P= .42). BM is the preferred graft for first chronic phase CML, whereas as either graft is suitable for other leukemias.",
keywords = "Chronic graft-versus-host disease, Leukemia, Mortality",
author = "Mary Eapen and Logan, {Brent R.} and Appelbaum, {Fredrick R.} and Antin, {Joseph H.} and Claudio Anasetti and Couriel, {Daniel R.} and Junfang Chen and Richard Maziarz and McCarthy, {Philip L.} and Ryotaro Nakamura and Voravit Ratanatharathorn and Ravi Vij and Champlin, {Richard E.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2014.09.006",
language = "English (US)",
volume = "21",
pages = "55--59",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy

AU - Eapen, Mary

AU - Logan, Brent R.

AU - Appelbaum, Fredrick R.

AU - Antin, Joseph H.

AU - Anasetti, Claudio

AU - Couriel, Daniel R.

AU - Chen, Junfang

AU - Maziarz, Richard

AU - McCarthy, Philip L.

AU - Nakamura, Ryotaro

AU - Ratanatharathorn, Voravit

AU - Vij, Ravi

AU - Champlin, Richard E.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - We sought to determine whether differences in chronic graft-versus-host disease (GVHD) rates would lead to survival differences by comparing 2463 peripheral blood (PB) and 1713 bone marrow (BM) hematopoietic cell transplant recipients. Patients had acute leukemia, chronic myeloid leukemia (CML), or myelodysplastic syndrome, and they received myeloablative conditioning regimens and calcineurin-inhibitor GVHD prophylaxis. There were no significant differences in long-term survival after transplantation of PB and BM, except for patients in first chronic phase CML. For these patients, the 5-year rate of survival was lower after transplantation of PB compared with transplantation of BM (35% versus 56%, P= .001). Although mortality risks were higher in patients with chronic GVHD after both PB (hazard ratio [HR], 1.58; P <.001) and BM (HR 1.73; P <.001) transplantations, its effect on mortality did not differ by graft type (P= .42). BM is the preferred graft for first chronic phase CML, whereas as either graft is suitable for other leukemias.

AB - We sought to determine whether differences in chronic graft-versus-host disease (GVHD) rates would lead to survival differences by comparing 2463 peripheral blood (PB) and 1713 bone marrow (BM) hematopoietic cell transplant recipients. Patients had acute leukemia, chronic myeloid leukemia (CML), or myelodysplastic syndrome, and they received myeloablative conditioning regimens and calcineurin-inhibitor GVHD prophylaxis. There were no significant differences in long-term survival after transplantation of PB and BM, except for patients in first chronic phase CML. For these patients, the 5-year rate of survival was lower after transplantation of PB compared with transplantation of BM (35% versus 56%, P= .001). Although mortality risks were higher in patients with chronic GVHD after both PB (hazard ratio [HR], 1.58; P <.001) and BM (HR 1.73; P <.001) transplantations, its effect on mortality did not differ by graft type (P= .42). BM is the preferred graft for first chronic phase CML, whereas as either graft is suitable for other leukemias.

KW - Chronic graft-versus-host disease

KW - Leukemia

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=84927166028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927166028&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.09.006

DO - 10.1016/j.bbmt.2014.09.006

M3 - Article

VL - 21

SP - 55

EP - 59

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1

ER -